CERENO SCIENTIFIC AB B (F:4A1) — Market Cap & Net Worth
Market Cap & Net Worth: CERENO SCIENTIFIC AB B (4A1)
CERENO SCIENTIFIC AB B (F:4A1) has a market capitalization of $155.87 Million (€133.33 Million) as of August 1, 2026. Listed on the F stock exchange, this Germany-based company holds position #17449 globally and #1645 in its home market, demonstrating a 1.66% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CERENO SCIENTIFIC AB B's stock price €0.43 by its total outstanding shares 310931744 (310.93 Million). Review CERENO SCIENTIFIC AB B balance sheet liabilities to assess the company's total debt and financial obligations.
CERENO SCIENTIFIC AB B Market Cap History: 2021 to 2026
CERENO SCIENTIFIC AB B's market capitalization history from 2021 to 2026. Data shows growth from $169.21 Million to $155.87 Million (8.21% CAGR).
CERENO SCIENTIFIC AB B Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CERENO SCIENTIFIC AB B's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4A1 by Market Capitalization
Companies near CERENO SCIENTIFIC AB B in the global market cap rankings as of August 1, 2026.
Key companies related to CERENO SCIENTIFIC AB B by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.50 |
CERENO SCIENTIFIC AB B Historical Marketcap From 2021 to 2026
Between 2021 and today, CERENO SCIENTIFIC AB B's market cap moved from $169.21 Million to $ 155.87 Million, with a yearly change of 8.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €155.87 Million | -32.47% |
| 2025 | €230.83 Million | +38.53% |
| 2024 | €166.63 Million | +3.01% |
| 2023 | €161.76 Million | +154.87% |
| 2022 | €63.47 Million | -62.49% |
| 2021 | €169.21 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of CERENO SCIENTIFIC AB B was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $155.87 Million USD |
| MoneyControl | $155.87 Million USD |
| MarketWatch | $155.87 Million USD |
| marketcap.company | $155.87 Million USD |
| Reuters | $155.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CERENO SCIENTIFIC AB B
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden and internationally. The company's lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an … Read more